A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

Anthony Mato,¹ Alexey Danilov,² Manish R. Patel,³ Michael Tees,⁴ Ian Flinn,⁵ Weiyun Ai,⁶ Krish Patel,⁷ Michael Tees,⁴ Ian Flinn,⁵ Weiyun Ai,⁶ Krish Patel,⁷ Michael Wang,⁸ Susan O'Brien,⁹ Srinand Nandakumar,¹⁰ Melissa A. Gessner,¹⁰ Su Young Kim,¹⁰ Adrian Wiestner,¹¹ William G. Wierda⁸

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²City of Hope National Medical Center, CA, USA; ³Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL, USA; ³Florida Cancer Specialists, Sarah Cannon Research Institute, San Francisco CA, USA; ³Florida Cancer Specialists, Sarah Cannon Research Institute, San Francisco CA, USA; ³Florida Cancer Specialists, Sarah Specialists, Sarah Cancer Sp ⁷Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA, USA; ¹⁰Nurix Therapeutics, Inc., San Francisco, CA, USA; ¹¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; ¹⁰Nurix Therapeutics, Inc., San Francisco, CA, USA; ¹¹National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; ¹⁰Nurix Therapeutics, Inc., San Francisco, CA, USA; ¹⁰Nurix Therapeutics, Inc.

Background

- Inhibiting Bruton's tyrosine kinase (BTK) has been shown to be effective in treating B-cell malignancies:
- Mutations in the BTK protein that prevent inhibitors from binding can cause resistance to approved BTK inhibitors.¹
- BTK degradation may offer an alternative method of interrupting B-cell receptor signaling and overcoming such resistance.
- Immunomodulatory drugs utilizing cereblon activity, such as lenalidomide and pomalidomide, can increase T-cell release of interferon gamma and interleukin-2 leading to anti-tumor activity in some B-cell malignancies.
- Chimeric targeting molecules catalyze ubiquitination and proteasomal degradation of target proteins and are comprised of a ubiquitin ligase-binding element ("harness"), a linker, and a target-binding element ("hook"):²
- NX-2127 is a chimeric targeting molecule that contains a BTK hook linked to a cereblon harness.²
- In addition to inducing BTK degradation, NX-2127 possesses activity similar to immunomodulatory drugs utilizing cereblon activity.²
- The combination of BTK degradation and immunomodulatory activity may be an effective strategy for treating relapsed/ refractory B-cell malignancies.

Methods


- NX-2127-001 is a first-in-human, Phase 1a (dose escalation) and Phase 1b (cohort expansion) study designed to evaluate the safety, tolerability, and preliminary efficacy of NX-2127 in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell malignancies with once daily oral dosing:
- Phase 1a (dose escalation) will proceed using an accelerated modified Fibonacci dose escalation design that transitions to a standard 3 + 3 design based on protocol-specific criteria.
- Phase 1b (cohort expansion) will include up to 5 expansion cohorts in the indications listed.
- The primary objectives are:
- To evaluate safety and tolerability and to determine the maximum tolerated dose (Phase 1a).
- To evaluate the early clinical activity of NX-2127 in expansion cohorts (Phase 1b).


References

- **1.** Woyach J A, et al J Clin Oncol. 2017;35:1437-43.
- **2.** Robbins DW, et al. Blood. 2020:136 (Supp 1): abst 34.
- **3.** Hallek M, et al. Blood. 2018;131:2745-60.
- **4.** Owen RG, et al. Br J Haematol. 2013;160:171-6.
- 5. Cheson et al. J Clin Oncol. 2014;32:3059-68.

Acknowledgements

- The authors would like to thank the patients and study coordinators who are taking part in this study.
- NX-2127-001 was sponsored by Nurix Therapeutics, Inc.






NX-2127: Structure and mechanism of action

NX-2127-001: Study design

Two-part first-in-human phase 1 monotherapy trial of NX-2127 in relapsed or refractory B-cell malignancies



*One patient/cohort in absence of Grade 2+ toxicity; 3+3 patients/cohort on 1st occurrence of Grade 2+ toxicity. [†]Total N dependent on # dose levels investigated and will include 6 patients at dose selected for Phase 1b for additional analysis of safety, pharmacodynamics, clinical activity,

Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; WM, Waldenström macroglobulinemia

• Nurix Therapeutics, Inc. also funded the provision of editorial support provided by Miller Medical Communications.

Study objectives and endpoints

Phase	Objectives	Endpoints
Primary (1a)	 Evaluate the safety and tolerability of BTK degrader NX-2127, when taken orally, in adult patients with relapsed/refractory B-cell malignancies Establish the MTD and/or recommended Phase 1b dose of NX-2127 	 Incidence of DLTs, TEAEs, Grade ≥3 TEAEs, SAEs, TEAEs leading to study drug discontinuation, and deaths due to TEAEs Incidence of all deaths Changes from baseline in safety parameters
Secondary (1a)	 Characterize the PK and PD profiles Characterize any relationship between PK/PD Assess preliminary anti-tumor activity 	 NX-2127 PK parameters in plasma (C_{max}, T_{max}, half-life, AUC_{0-last}, AUC_{0-inf}, AUC_{0-tau}, C_{min}, accumulation ratio) Changes from baseline of BTK levels in B cells ORR, CR rate / CRi rate, DOR, PFS
Primary (1b)	 Evaluate the clinical activity at the recommended dose selected in Phase 1a in up to 5 relapsed/refractory B-cell malignancy indication populations 	 ORR based on B-cell malignancy indication-specific criteria, i.e.: iwCLL criteria³ for CLL/SLL WM response criteria4 for WM Lugano Classification of Lymphoma response criteria5 for DLBCL, FL, MCL, and MZL
Secondary (1b)	 Evaluate safety and tolerability Further characterize anti-tumor activity Further characterize PK and PD profiles Further characterize any relationship between PK/PD and anti-tumor activity 	 Incidence of TEAEs, Grade ≥3 TEAEs, deaths due to TEAEs, SAEs, TEAEs leading to discontinuation, and changes in safety parameters Incidence of all deaths NX-2127 PK parameters in plasma Changes from baseline of BTK levels in B cells CR rate / CRi rate, DOR, PFS, OS

cell lymphoma; MTD, maximum tolerated dose; MZL, marginal zone lymphoma; ORR, objective response rate; OS, overall survival; PD, pharmacodynamics; PFS, progression-free survival; PK, pharmacokinetics; SAEs, serious adverse events; TEAEs, treatment-emergent adverse events; T_{max} , time to C_{max} ; WM, Waldenström macroglobulinemia

Target population

Phase 1a Dose escalation

• Adult patients with histologically confirmed relapsed/refractory B-cell malignancies

- Patients required to have any the following: CLL/SLL with no BTK C481 mutation cohort - CLL, SLL, MCL, MZL, WM, FL (grade 1–3b), or DLBCL (high-grade B-cell lymphoma, with MYC • CLL or SLL with no BTK C481 mutation whose disease has failed treatment with a BTKi and BCL2 and/or BCL6 rearrangements and high-grade B-cell lymphoma NOS)
- Patients must have required and received at least 2 prior systemic therapies (or 1 prior therapy for patients with WM), and for whom no other therapies are known to provide clinical benefit

Ubiquitin

Note: Failed treatment in Phase 1b is defined as: i) Best response of stable disease during treatment and then subsequently had progressive disease; ii) Any response with secondary progression; or iii) Best response of progressive disease at any time while on therapy. *Abbreviations:* BTK, Bruton's tyrosine kinase; BTKi, BTK inhibitor; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; mAb, monoclonal antibody; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NOS, not otherwise specified; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia

Key eligibility criteria

Abbreviated inclusion criteria

- ≥18 years of age
- At least 2 weeks must have elapsed between the last therapy and the first dose of study drug or at least 4 weeks for antibody-containing therapies, except for patients with CLL on a small molecule therapy who require at least 5 halflives or 2 days (whichever is longer)
- Must require systemic therapy
- Patients must have radiographically measurable disease per response criteria specific to the malignancy
- ECOG performance status of 0 or 1
- Adequate organ and bone marrow function, in the absence of growth factors, as defined per protocol laboratory parameters

- prior CAR-T therapy

- Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for
- peripheral neuropathy, or hematologic parameters meeting inclusion criteria)
- Patients requiring ongoing treatment with warfarin or patients treated with dual anti-platelet therapy and vitamin K antagonists

Current status

- Phase 1a dose escalation is ongoing in non-CLL indications.
- Phase 1b dose expansion is currently enrolling for patients with CLL.
- Clinical trial information: NCT04830137.
- Study contact: nx2127001@nurixtx.com

Phase 1b Cohort expansion

- CLL/SLL with BTK C481 mutation cohort • BTK C481 mutation-positive CLL/SLL whose disease has failed treatment with a BTKi

MCL, MZL, WM cohort

- MCL or MZL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen or WM whose disease has failed treatment with BTKi
- **Relapsed/refractory FL cohort**
- FL (grade 1–3b) whose disease has failed treatment with an anti-CD20 mAb-based regimen
- **Relapsed/refractory DLBCL cohort**
- DLBCL (including transformed FL and transformed MZL; not Richter's) whose disease has failed treatment with an anti-CD20 mAb-based regimen and an anthracycline. DLBCL histologies include high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements and highgrade B-cell lymphoma NOS

Abbreviated exclusion criteria

Richter's transformation, prolymphocytic leukemia, or blastoid transformation of FL into DLBCL prior to planned start of study drug • Patients who have undergone autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug History of CAR-T therapy within 100 days prior to start of study drug. Must have evidence of B-cell recovery if patient received

• Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)

• Prior chemotherapy within 2 weeks of planned start of study drug

- Prior monoclonal antibody therapy within 4 weeks of planned start of study drug
- alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy,
- History of Grade ≥2 hemorrhage within 28 days
- Abbreviations: CAR-T, Chimeric Antigen Receptor T-cell; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; WM, Waldenström macroglobulinemia



